Benlysta – pro
BELIMUMAB (Benlysta) is a targeted, human monoclonal antibody that binds to soluble B lymphocyte stimulator (BLyS). Benlysta is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of Benlysta is not recommended in these situations.
Benlysta is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
Benlysta, Prescribing Information, 2018
van Vollenhoven RF, et al. Belimumab in the treatment of systemic lupus erythematosus: high
disease activity predictors of response. Ann Rheum Dis. 2012;71:1343-1349.
Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet. 2011; 377:721-31.
Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6:CD002922